Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biora Therapeutics, Inc. - Common Stock (NQ: BIOR )

5.980 +0.690 (+13.04%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 894,210
Open 5.410
Bid (Size) 5.910 (1)
Ask (Size) 6.020 (1)
Prev. Close 5.290
Today's Range 5.300 - 6.700
52wk Range 1.950 - 28.75
Shares Outstanding 4,005,230
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
From Biora Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+154.47%
+154.47%
1 Month
+110.56%
+110.56%
3 Month
+119.85%
+119.85%
6 Month
+21.24%
+21.24%
1 Year
-68.79%
-68.79%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024
Via InvestorPlace
Recap: Biora Therapeutics Q1 Earnings
Via Benzinga
Earnings Preview: Biora Therapeutics
Via Benzinga
Biora Therapeutics Earnings Perspective: Return On Invested Capital
Via Benzinga
Earnings Preview For Biora Therapeutics
Via Benzinga
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Participate in Crohn’s & Colitis Foundation’s IBD Innovate Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
What Does Biora Therapeutics' Debt Look Like?
Via Benzinga
Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Improved Bioavailability Results for its Systemic Delivery Platform
From Biora Therapeutics, Inc.
Via GlobeNewswire
10 Short Squeeze Candidates To Watch This Week: Getty Images, PaxMedica And This Meme Stock Retailer
Via Benzinga
Biora Therapeutics' Debt Overview
Via Benzinga
Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress
From Biora Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Benzinga 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring, But Not Yet Talking About
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why KNOT Offshore Partners Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.